Wechselwirkungen · Xigduo
Xigduo 5 mg/850 mg film-coated tablets Xigduo 5 mg/1,000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-128335 · Präparat HOS-096549
In interaction studies conducted in healthy subjects, using mainly a single-dose design, dapagliflozin did not alter the pharmacokinetics of pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate) or warfarin (S-warfarin, a CYP2C9 substrate), or the anti-coagulatory effects of warfarin as measured by INR. Combination of a single dose of dapagliflozin 20 mg and simvastatin (a CYP3A4 substrate) resulted in a 19% increase in AUC of simvastatin and 31% increase in AUC of simvastatin acid. The increase in simvastatin and simvastatin acid exposures are not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glimepiride (HOS-112373) dapagliflozin (HOS-125333) hydrochlorothiazide (HOS-086937) simvastatin (HOS-086158) digoxin (HOS-086172) pioglitazone (HOS-089663) bumetanide (HOS-125088) valsartan (HOS-088810) sitagliptin (HOS-117222) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T13:14:00Z · SHA-256 5e4e22027f26f36b3af00f1144f882799bae35ea23b1602e05670ab58107afc7 · Passage 686a14fb1d4b0dcfa6a0e757de696cf9fdb9ff9fcca68b9254b1748aa49d5ef0 · Zeichen 2770–3413 im Abschnitt